eFFECTOR Therapeutics (EFTR) Stock Forecast, Price Target & Predictions
EFTR Stock Forecast
eFFECTOR Therapeutics stock forecast is as follows: an average price target of $5.50 (represents a 2749900.07% upside from EFTR’s last price of -) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
EFTR Price Target
The average price target for eFFECTOR Therapeutics (EFTR) is $5.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $1.00. This represents a potential 2749900.07% upside from EFTR's last price of -.
EFTR Analyst Ratings
According to 2 Wall Street analysts, eFFECTOR Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for EFTR stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
eFFECTOR Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 04, 2024 | Stifel Nicolaus | $10.00 | $2.96 | 237.84% | 4999900.13% | |
| Jan 09, 2023 | JMP Securities | $1.00 | $0.44 | 127.32% | 499900.01% |
The latest eFFECTOR Therapeutics stock forecast, released on Apr 04, 2024 by Stifel Nicolaus company, set a price target of $10.00, which represents a 237.84% increase from the stock price at the time of the forecast ($2.96), and a 4999900.13% increase from EFTR last price (-).
eFFECTOR Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $10.00 |
| Last Closing Price | - | - | - |
| Upside/Downside | -100.00% | -100.00% | 4999900.13% |
In the current month, the average price target of eFFECTOR Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to eFFECTOR Therapeutics's last price of -. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 09, 2023 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Jan 06, 2023 | Credit Suisse | Outperform | Outperform | Hold |
| Nov 17, 2022 | JMP Securities | Market Outperform | Market Outperform | Hold |
eFFECTOR Therapeutics's last stock rating was published by JMP Securities on Jan 09, 2023. The company gave EFTR a "Market Outperform" rating, the same as its previous rate.
eFFECTOR Therapeutics Financial Forecast
eFFECTOR Therapeutics Revenue Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $664.40K | $802.75K | $420.00K | $280.00K | $100.00K |
| High Forecast | - | - | - | - | $664.40K | $802.75K | $420.00K | $280.00K | $100.00K |
| Low Forecast | - | - | - | - | $664.40K | $802.75K | $420.00K | $280.00K | $100.00K |
| # Analysts | 1 | 1 | 1 | 2 | - | - | - | - | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - |
eFFECTOR Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. EFTR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
eFFECTOR Therapeutics EBITDA Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | - | - | - | - | 1 |
| EBITDA | - | - | - | - | $-8.72M | - | - | $-7.21M | $-12.40M |
| Avg Forecast | - | - | - | - | $50.79K | $61.37K | $32.11K | $111.38K | $7.64K |
| High Forecast | - | - | - | - | $50.79K | $61.37K | $32.11K | $133.65K | $7.64K |
| Low Forecast | - | - | - | - | $50.79K | $61.37K | $32.11K | $89.10K | $7.64K |
| Surprise % | - | - | - | - | -171.73% | - | - | -64.69% | -1622.37% |
undefined analysts predict EFTR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than eFFECTOR Therapeutics's previous annual EBITDA (undefined) of $NaN.
eFFECTOR Therapeutics Net Income Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | - | - | - | - | 1 |
| Net Income | - | - | - | - | $-9.80M | - | - | $12.69M | $18.56M |
| Avg Forecast | $-3.65M | $-6.27M | $-7.08M | $-8.84M | $-24.30M | $-21.82M | $-16.46M | $6.33M | $-24.51M |
| High Forecast | $-3.65M | $-6.27M | $-7.08M | $-8.84M | $-24.30M | $-21.82M | $-16.46M | $7.60M | $-24.51M |
| Low Forecast | $-3.65M | $-6.27M | $-7.08M | $-8.84M | $-24.30M | $-21.82M | $-16.46M | $5.06M | $-24.51M |
| Surprise % | - | - | - | - | 0.40% | - | - | 2.00% | -0.76% |
eFFECTOR Therapeutics's average Quarter net income forecast for Jul 22 is $-16.46M, with a range of $-16.46M to $-16.46M. EFTR's average Quarter net income forecast represents a -229.72% decrease compared to the company's last Quarter net income of $12.69M (Mar 22).
eFFECTOR Therapeutics SG&A Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | - | - | - | - | 1 |
| SG&A | - | - | - | - | $2.75M | - | - | $3.44M | $6.32M |
| Avg Forecast | - | - | - | - | $1.99M | $2.41M | $1.26M | $840.69K | $300.25K |
| High Forecast | - | - | - | - | $1.99M | $2.41M | $1.26M | $840.69K | $300.25K |
| Low Forecast | - | - | - | - | $1.99M | $2.41M | $1.26M | $840.69K | $300.25K |
| Surprise % | - | - | - | - | 1.38% | - | - | 4.09% | 21.05% |
eFFECTOR Therapeutics's average Quarter SG&A projection for Mar 24 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to EFTR last annual SG&A of $2.75M (Dec 22).
eFFECTOR Therapeutics EPS Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | - | - | - | - | 1 |
| EPS | - | - | - | - | $-0.24 | - | - | $0.31 | $0.46 |
| Avg Forecast | $-0.90 | $-1.53 | $-1.74 | $-2.17 | $-5.95 | $-5.35 | $-4.03 | $-5.93 | $-6.01 |
| High Forecast | $-0.90 | $-1.53 | $-1.74 | $-2.17 | $-5.95 | $-5.35 | $-4.03 | $-5.93 | $-6.01 |
| Low Forecast | $-0.90 | $-1.53 | $-1.74 | $-2.17 | $-5.95 | $-5.35 | $-4.03 | $-5.93 | $-6.01 |
| Surprise % | - | - | - | - | 0.04% | - | - | -0.05% | -0.08% |
According to 0 Wall Street analysts, eFFECTOR Therapeutics's projected average Quarter EPS for Jul 22 is $-4.03, with a low estimate of $-4.03 and a high estimate of $-4.03. This represents a -1400.63% decrease compared to EFTR previous annual EPS of $0.31 (Mar 22).